Biosun Pharma
Latest round
- Series C
Last raised
- May 2025
Total raised
- Undisclosed
Investors
- 4
About Biosun Pharma
Founded in 2020 and based in Hangzhou, China, Biosun Pharma operates as a biomedical technology company that provides molecular targeting and antibody drugs for tumors, autoimmune diseases and inflammatory diseases. The company has clinical operations branches in Hangzhou, Chengdu, Changsha, and Zhengzhou. The company engages in the development of drugs for tumors, autoimmune diseases, and inflammatory diseases. Its product Bangsairuini completed the phase III clinical study. Products applicable to myeloproliferative neoplasms, lymphomas and other blood diseases. Besides, it is developing Bangsatini for autoimmune diseases, such as immune thrombocytopenia (ITP), chronic immune urticaria, and chronic graft-versus-host diseases. The company generates revenue by doing research, development and providing molecular targeted and antibody drugs.
Who invested in Biosun Pharma
4 investors across 3 rounds
See all investors in Biosun Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Biosun Pharma
Who invested in Biosun Pharma?
Biosun Pharma has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biosun Pharma raised?
Biosun Pharma has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Biosun Pharma last raise money?
Biosun Pharma's most recent round on record is a Series C, in May 2025.
What does Biosun Pharma do?
Founded in 2020 and based in Hangzhou, China, Biosun Pharma operates as a biomedical technology company that provides molecular targeting and antibody drugs for tumors, autoimmune diseases and inflammatory diseases.
Where is Biosun Pharma headquartered?
Biosun Pharma is headquartered in Hangzhou, China.
Which VCs invest in companies like Biosun Pharma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Biosun Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Biosun Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.